AR103728A1 - Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2 - Google Patents
Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2Info
- Publication number
- AR103728A1 AR103728A1 ARP160100435A ARP160100435A AR103728A1 AR 103728 A1 AR103728 A1 AR 103728A1 AR P160100435 A ARP160100435 A AR P160100435A AR P160100435 A ARP160100435 A AR P160100435A AR 103728 A1 AR103728 A1 AR 103728A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- dimetoxifenilos
- monoamine transporter
- vesicular monoamine
- deuterium
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 title 1
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 title 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 3
- 229910052805 deuterium Inorganic materials 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117654P | 2015-02-18 | 2015-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103728A1 true AR103728A1 (es) | 2017-05-31 |
Family
ID=56692737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100435A AR103728A1 (es) | 2015-02-18 | 2016-02-18 | Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10722479B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3258926A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018507210A (cg-RX-API-DMAC7.html) |
| AR (1) | AR103728A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017017673A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2976229A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201791839A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL253901A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA41557A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017010567A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201630871A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016133989A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ211815A (en) | 1984-05-15 | 1988-11-29 | Warner Lambert Co | Preparation of 1-((3,4-dimethoxyphenethyl)amino)-3- (3-tolyloxy)-2-propanol |
| EP2032525A1 (en) * | 2006-05-26 | 2009-03-11 | Auspex Pharmaceuticals Inc. | Deuterated aminoglycidyl compounds |
| CA2701638A1 (en) | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals Inc. | Pharmaceutical calcimimetics |
| US20100009950A1 (en) * | 2008-06-30 | 2010-01-14 | Auspex Pharmaceuticals, Inc. | Substituted ethanolamines |
| NO3061760T3 (cg-RX-API-DMAC7.html) * | 2008-09-18 | 2018-04-07 | ||
| US20100143287A1 (en) | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Trifluoromethylphenyl modulators of calcium-sensing receptor |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| NZ705372A (en) * | 2012-09-18 | 2018-07-27 | Auspex Pharmaceuticals Inc | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| DK3010543T3 (da) | 2013-06-19 | 2025-12-01 | Som Innovation Biotech S A | Terapeutiske midler til anvendelse i profylakse og/eller behandling af hyperkinetiske bevægelsesforstyrrelser |
-
2016
- 2016-02-16 MA MA041557A patent/MA41557A/fr unknown
- 2016-02-17 US US15/550,152 patent/US10722479B2/en active Active
- 2016-02-17 EP EP16752959.3A patent/EP3258926A4/en not_active Withdrawn
- 2016-02-17 BR BR112017017673A patent/BR112017017673A2/pt not_active Application Discontinuation
- 2016-02-17 WO PCT/US2016/018222 patent/WO2016133989A1/en not_active Ceased
- 2016-02-17 JP JP2017543828A patent/JP2018507210A/ja active Pending
- 2016-02-17 CA CA2976229A patent/CA2976229A1/en not_active Abandoned
- 2016-02-17 MX MX2017010567A patent/MX2017010567A/es unknown
- 2016-02-17 EA EA201791839A patent/EA201791839A1/ru unknown
- 2016-02-18 TW TW105104725A patent/TW201630871A/zh unknown
- 2016-02-18 AR ARP160100435A patent/AR103728A1/es unknown
-
2017
- 2017-08-08 IL IL253901A patent/IL253901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018507210A (ja) | 2018-03-15 |
| EP3258926A4 (en) | 2018-11-14 |
| BR112017017673A2 (pt) | 2018-07-17 |
| WO2016133989A1 (en) | 2016-08-25 |
| TW201630871A (zh) | 2016-09-01 |
| IL253901A0 (en) | 2017-10-31 |
| MX2017010567A (es) | 2018-03-16 |
| MA41557A (fr) | 2017-12-26 |
| EA201791839A1 (ru) | 2018-02-28 |
| US20180036260A1 (en) | 2018-02-08 |
| CA2976229A1 (en) | 2016-08-25 |
| US10722479B2 (en) | 2020-07-28 |
| EP3258926A1 (en) | 2017-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| GT201700189A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| NI201800133A (es) | Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2018003474A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| CR20170564A (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| CL2019000512A1 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| CR20180057A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. | |
| AR104174A1 (es) | Oxadiazoles sustituidos con deuterio | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| AR103355A1 (es) | Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística | |
| CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| MX2019013645A (es) | Inhibidores de quinasa y usos de los mismos. | |
| CO2018003367A2 (es) | Benzamidas sustituidas con isoxazolina y análogos como insecticidas | |
| BR112017006240A2 (pt) | novos compostos | |
| CR20180143A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| MX2018009459A (es) | Derivado de sulfonamida y composicion farmaceutica que contiene el mismo. | |
| AR103317A1 (es) | Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina | |
| BR112016027691A2 (pt) | Composto de tetra-hidropiridopirimidina e seus usos | |
| AR103316A1 (es) | Inhibidores de dihidroquinazolina de terminasa viral | |
| AR103354A1 (es) | INHIBIDORES DE 3-FLUORO-BENZONITRILO DE 11-b-HIDROXILASA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |